Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CUE

Cue Biopharma Inc

May 01 • 02:45PM ET

33.11

+18.37 124.62 %

Healthcare • Biotechnology • USA • Micro • NASD

Apr 30, 4:30 PMCue Biopharma raises $30M in PIPE financing at effective $11.00 per unit to fund clinical pipeline and Ascendant-221

Peers: AMGN BMY GILD BMRN REGN BIIB VRTX INCY SAGE FATE

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.40	Insider Own	0.56%	Shs Outstand	3.26M	Perf Week	87.11%
Market Cap	107.77M	Forward P/E	-	EPS next Y	-18.00	Insider Trans	-	Shs Float	3.24M	Perf Month	444.74%
Enterprise Value	84.83M	PEG	-	EPS next Q	-	Inst Own	22.31%	Short Float	7.76%	Perf Quarter	229.64%
Income	-26.60M	P/S	3.92	EPS this Y	-107.14%	Inst Trans	-	Short Ratio	0.68	Perf Half Y	59.95%
Sales	27.47M	P/B	4.03	EPS next Y	-3.45%	ROA	-70.62%	Short Interest	0.25M	Perf YTD	261.38%
Book/sh	8.21	P/C	3.97	EPS next 5Y	-	ROE	-121.11%	52W High	30.97 6.91%	Perf Year	46.80%
Cash/sh	8.34	P/FCF	-	EPS past 3/5Y	42.63% 29.04%	ROIC	-92.63%	52W Low	4.97 566.05%	Perf 3Y	-75.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	180.45% 54.16%	Gross Margin	95.89%	Volatility	48.82% 41.40%	Perf 5Y	-90.90%
Dividend TTM	-	EV/Sales	3.09	EPS Y/Y TTM	58.21%	Oper. Margin	-96.56%	ATR (14)	5.81	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.74	Sales Y/Y TTM	195.75%	Profit Margin	-96.85%	RSI (14)	71.59	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.74	EPS Q/Q	111.21%	SMA20	108.73%	Beta	2.39	Target Price	120.00
Payout	-	Debt/Eq	0.16	Sales Q/Q	1292.26%	SMA50	194.19%	Rel Volume	58.39	Prev Close	14.74
Employees	29	LT Debt/Eq	0.09	Earnings	Mar 16 AMC	SMA200	98.83%	Avg Volume	370.56K	Price	33.11
IPO	Jan 02, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	111.11% 2094.20%	Trades		Volume	17,683,762	Change	124.62%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-24	Initiated	Jefferies	Buy	$6
Jun-26-23	Resumed	Oppenheimer	Outperform	$10
Nov-21-22	Initiated	Piper Sandler	Overweight	$7
Jan-13-22	Initiated	H.C. Wainwright	Buy	$20
Jan-03-22	Initiated	Craig Hallum	Buy	$28
Nov-24-20	Initiated	Berenberg	Buy	$30
Apr-09-20	Initiated	Stifel	Buy	$21
Jan-28-20	Initiated	BTIG Research	Buy	$26
Jan-22-20	Initiated	JMP Securities	Mkt Outperform	$22

Apr-30-26 04:25PM	Cue Biopharma Announces $30 Million Private Placement (GlobeNewswire) +13.38% +124.62%
04:15PM	Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody (GlobeNewswire)
04:05PM	Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company (GlobeNewswire)
Apr-22-26 08:37AM	Cue Biopharma Announces 1-for-30 Reverse Stock Split (GlobeNewswire) -13.42%
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +65.37%
08:00AM	Loading…
08:00AM	Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 (GlobeNewswire)
Apr-10-26 10:30AM	BC-Most Active Stocks (Associated Press) +71.36%
Apr-08-26 08:00AM	Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement (GlobeNewswire) +45.48%
Apr-07-26 10:30AM	BC-Most Active Stocks (Associated Press) +6.33%
Mar-27-26 04:05PM	Cue Biopharma Announces CEO Transition (GlobeNewswire) -5.60%
Mar-26-26 08:00AM	Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 (GlobeNewswire) -5.03%
Mar-16-26 04:05PM	Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire) +9.80% -12.84%
Mar-09-26 08:00AM	Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 (GlobeNewswire)
Feb-17-26 08:00AM	Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.06%
Feb-12-26 08:00AM	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer (GlobeNewswire) -6.75%
08:00AM	Loading…
Dec-19-25 08:00AM	Cue Biopharma Announces Pricing of $10 Million Public Offering (GlobeNewswire) -21.58%
Dec-18-25 04:02PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire) -14.50%
Nov-12-25 05:25PM	Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.19%
04:05PM	Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-25 05:55PM	CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-06-25 06:00PM	Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates (Zacks)
08:00AM	Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors (GlobeNewswire)
Nov-05-25 06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-30-25 08:20AM	Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Sep-29-25 09:00AM	Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates (GlobeNewswire)
Aug-21-25 08:00AM	Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-13-25 08:00AM	Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme (GlobeNewswire)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-08-25 07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Loading…
Aug-07-25 06:00PM	scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-16-25 08:00AM	Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer (GlobeNewswire) +22.29%
Jul-01-25 04:05PM	Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire)
Jun-24-25 04:48PM	Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease (GlobeNewswire) +10.43% +8.67%
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-25 08:00AM	Cue Biopharma to Host Virtual Investor Event on May 15, 2025 (GlobeNewswire)
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-25 10:00AM	Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
May-01-25 10:01AM	Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-30-25 09:30AM	Boehringer, Oxford University and Cumulus to explore brain activity in BPD (Pharmaceutical Technology)
Apr-16-25 04:58AM	Boehringer and Cue Biopharma to develop autoimmune therapies (Pharmaceutical Technology)
Apr-15-25 06:12PM	Cue Biopharma, Inc. (CUE) Business Update Call (Transcript) (Seeking Alpha)
02:00AM	Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire)
Apr-14-25 10:23PM	Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering (GlobeNewswire)
05:05PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire)
05:02PM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
05:00PM	Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire)
Mar-31-25 05:15PM	Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -17.67%
04:20PM	Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
Mar-28-25 09:15AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.00%
Nov-29-24 04:30PM	Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 08:00AM	Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-14-24 05:25PM	Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -17.00%
04:05PM	Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
08:00AM	Cue Biopharma Announces Strategic Organizational Transition (GlobeNewswire)
Nov-12-24 08:00AM	Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference (GlobeNewswire) -9.09%
Nov-08-24 01:30PM	Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting (GlobeNewswire)
Oct-04-24 09:00AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +41.60%
Sep-26-24 11:26PM	Cue Biopharma Announces Pricing of $12.0 Million Public Offering (GlobeNewswire) +49.61%
11:10PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire)
Sep-09-24 08:00AM	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer (GlobeNewswire)
Sep-03-24 08:00AM	Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference (GlobeNewswire) -8.96%
Aug-20-24 09:36AM	Q2 2024 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) +13.68%
Aug-19-24 04:05PM	Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +11.93%
Aug-14-24 07:45PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-13-24 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Jul-26-24 10:13AM	Cue Biopharma downsizes to focus on autoimmune pipeline (Pharmaceutical Technology)
Jul-25-24 04:05PM	Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements (GlobeNewswire)
Jun-04-24 08:00AM	Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting (GlobeNewswire) -5.45%
Jun-03-24 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 (GlobeNewswire)
May-30-24 03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-09-24 11:54PM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -9.14%
04:05PM	Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-24 08:00AM	Cue Biopharma to Present at the 20th Annual PEGS Boston Summit (GlobeNewswire) -12.39%
May-07-24 08:00AM	Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-25-24 09:35AM	Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks (Zacks)
Apr-24-24 10:01AM	Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.33%
Apr-15-24 09:55AM	Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now (Zacks) -8.86%
Apr-09-24 07:36AM	Q4 2023 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -6.86%
03:02AM	Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ... (GuruFocus.com)
Apr-08-24 04:05PM	Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights (GlobeNewswire) +10.27%
Apr-02-24 01:53PM	CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Feb-29-24 10:00AM	Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium (GlobeNewswire)
Feb-06-24 08:00AM	Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.46%
Dec-14-23 07:04AM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023 (InvestorPlace)
Nov-22-23 08:00AM	Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-12-23 12:55PM	Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -11.32% +11.33%
Nov-07-23 08:00AM	Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November (GlobeNewswire)
Nov-03-23 12:00PM	Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023 (GlobeNewswire) +10.36%
Nov-02-23 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire) +9.90%
Sep-28-23 05:39AM	Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains? (Zacks)
Sep-27-23 09:05AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-26-23 08:00AM	Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA® (GlobeNewswire) +5.83%
Aug-10-23 10:37AM	Q2 2023 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -13.26%
10:19AM	Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call Transcript (Insider Monkey)

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sarraf Pasha	Director	Dec 30 '25	Buy	0.31	323,857	99,747	323,857	Jan 02 04:00 PM
MATTEO GIACOMO LEVISETTI	Officer	Dec 29 '25	Proposed Sale	0.26	7,230	1,907		Dec 29 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CUE

Cue Biopharma Inc

Upgrade your Finviz experience